Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca Standardizes Marketing Methods Worldwide
September 19, 2005
- Dr Iwasaki of EFPIA Japan Proposes Multiple-consultation System
September 19, 2005
- IIC of Germany to Support Investment in Diagnostics, Med. Device Fields
September 19, 2005
- Workshop on Stem Cells Cosponsored by Schering AG
September 19, 2005
- Canada to Extend Data Protection to 8 Years: Forum
September 19, 2005
- R&D NEWS IN BRIEF -1-
September 19, 2005
- BUSINESS NEWS IN BRIEF
September 19, 2005
- R&D NEWS IN BRIEF -2-
September 19, 2005
- SEMINAR
September 19, 2005
- Chuikyo to Conduct Survey on Med. Institutions' Costs and IT
September 19, 2005
- Goodrug to Begin Internet Sale of Generics on Oct. 1
September 19, 2005
- Incidence of Abnormality Rose in All Age Brackets in 2004: Health Examinations
September 19, 2005
- Kyorin to Back Up Toyo Pharmar in Earnest
September 19, 2005
- Kenporen Calls For Reductions in Medical Fees
September 19, 2005
- SSP to Raise Its Corporate Value
September 19, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 19, 2005
- Korosho Considering Sharp Increases in Initial, Follow-up Consultation Fees
September 19, 2005
- SURVEY 2 articles
September 19, 2005
- ABMJ Proposes Fund for Development of New Influenza Vaccines
September 19, 2005
- TOPICS 2 articles
September 19, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…